EW - Edwards Lifesciences Corporation

NYSE - NYSE Delayed Price. Currency in USD
168.41
+9.30 (+5.85%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close159.11
Open163.00
Bid0.00 x 800
Ask200.00 x 900
Day's Range162.81 - 168.53
52 Week Range121.40 - 175.00
Volume2,305,443
Avg. Volume1,528,798
Market Cap35.206B
Beta (3Y Monthly)0.82
PE Ratio (TTM)50.68
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Markit2 days ago

    See what the IHS Markit Score report has to say about Edwards Lifesciences Corp.

    # Edwards Lifesciences Corp ### NYSE:EW View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for EW with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $7.74 billion over the last one-month into ETFs that hold EW are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • The Wall Street Journal3 days ago

    [$$] Stocks to Watch: Goldman Sachs, Bank of America, Ford, Sears, United Continental, Fiserv, Snap and Facebook

    Goldman Sachs, Bank of America, Ford, Sears, United Continental, Fiserv, Snap and Facebook are among Wednesday’s stocks to watch.

  • Associated Press4 days ago

    Netflix, UnitedHealth and Edwards climb; Wells Fargo dips

    Stocks that moved substantially or traded heavily Tuesday: Netflix Inc., up $21.70 to $354.64 The video streaming company said it will raise prices for its U.S. subscribers. Microsoft Corp., up $2.96 to ...

  • Why Netflix, First Republic Bank, and Edwards Lifesciences Jumped Today
    Motley Fool4 days ago

    Why Netflix, First Republic Bank, and Edwards Lifesciences Jumped Today

    Investors liked the streaming-video giant's latest move.

  • Why An IBD 50 Stock And Its Close Rival Are Nearing Breakouts
    Investor's Business Daily4 days ago

    Why An IBD 50 Stock And Its Close Rival Are Nearing Breakouts

    Edwards Lifesciences and Boston Scientific stocks hit one-month highs Tuesday after the duo settled a patent battle related to transcatheter aortic heart-valve replacements.

  • Indexes Close Higher As FANG Stocks Help Nasdaq Outperform
    Investor's Business Daily4 days ago

    Indexes Close Higher As FANG Stocks Help Nasdaq Outperform

    The stock market closed higher Tuesday after earnings reports and gains for the FANG stocks underscored the day's trading.

  • TheStreet.com4 days ago

    Edwards Lifesciences' Stock Jumps on Patent Dispute Settlement

    surged nearly 8% on Tuesday after the company agreed to pay rival Boston Scientific Corp. $180 million to settle long-standing patent disputes over heart valve replacement devices. At midday, Edwards Lifesciences' stock rose 8.4% to $162.09 at the close of trading on the New York Stock Exchange.

  • Boston Scientific settles global heart valve legal battles for $180M
    American City Business Journals4 days ago

    Boston Scientific settles global heart valve legal battles for $180M

    The tools Boston Scientific and Edwards Lifesciences have battled over are used during a relatively new, multibillion-dollar cardiac treatment called transcatheter aortic valve replacement (TAVR).

  • Boston Scientific and Edward Lifesciences Settle Patent Dispute
    Market Realist4 days ago

    Boston Scientific and Edward Lifesciences Settle Patent Dispute

    Boston Scientific and Edward Lifesciences Settle Patent DisputeThe stock performance of BSXToday, Boston Scientific (BSX) is trading at $36.76, which is ~4.11% growth from yesterday’s closing price of $35.31. Boston Scientific stock closed at

  • Tech Stocks Advance With These 2 Dow Jones Stocks Mixed On Earnings
    Investor's Business Daily4 days ago

    Tech Stocks Advance With These 2 Dow Jones Stocks Mixed On Earnings

    The tech-heavy Nasdaq composite led the way early Tuesday. Dow Jones stocks JPMorgan and UnitedHealth reported earnings results.

  • Reuters4 days ago

    Edward Lifesciences pays Boston Scientific $180 mln to end patent row

    Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers. Boston Scientific and Edwards Lifesciences have been embroiled in a number of legal cases for several years involving heart valve replacement systems, including transcatheter aortic valves, in the United States and Europe. All pending cases or appeals in courts and patent offices will be dismissed, the companies said in a joint statement on Tuesday.

  • Reuters4 days ago

    Edward Lifesciences settles patent disputes with Boston Scientific

    Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement related to all outstanding patent disputes between the companies, the medical device makers said in ...

  • Markit10 days ago

    See what the IHS Markit Score report has to say about Edwards Lifesciences Corp.

    # Edwards Lifesciences Corp ### NYSE:EW View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for EW with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding EW is favorable, with net inflows of $16.78 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • The 9 Best Stocks of America’s Last Bear Market
    Kiplinger11 days ago

    The 9 Best Stocks of America’s Last Bear Market

    It's official. The Nasdaq Composite has waded all the way into bear-market territory, now down 20% from its late-September peak. The Dow Jones Industrial Average and the Standard & Poor's 500-stock index aren't far behind. Whether the fourth-quarter selloff is merited doesn't entirely matter. If the crowd believes the rout suffered over the course of the past three months is the shape of things to come, stocks will lose more ground as investors create the very bear market they fear. It's a self-fulfilling prophecy. But here at the precipice of seeing the market's condition shift from bad to worse, remember: Not all stocks have to lose ground, even if the tide is going out. One only has to look at the nine big stocks that managed to gain ground between October 2007 and March 2009 - America's last bear market - to appreciate that some companies have staying power even in rough environments. Here are nine S&P; 500 stocks that actually gained in the face of the 2007-09 bear market. Notice in all nine cases, there was something unique about these organizations that shielded them from the full impact of economic woe. And in some cases, they still look properly positioned to fight off another bear attack. ### SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)

  • Can Edwards Lifesciences (EW) Keep the Earnings Surprise Streak Alive?
    Zacks11 days ago

    Can Edwards Lifesciences (EW) Keep the Earnings Surprise Streak Alive?

    Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Top 5 Health Care Stocks of 2018 by Performance
    Investopedia12 days ago

    Top 5 Health Care Stocks of 2018 by Performance

    The healthcare sector performed well in 2018, driven by positive growth in sub-segments such as medical devices, health insurance, hospitals, nursing homes, and pharmaceuticals, which offset losses in biomedical and genetics, home healthcare, medical, and dental supplies. Moving ahead into 2019, as the decade-long expansion faces a period of heightened volatility and risk, the health care sector should benefit from a shift towards more defensive sectors. In a recent sector roundup from Charles Schwab, the firm rated health care at "outperform," citing the group’s strong balance sheets, attractive dividend yields, and improved cost structure.

  • Will A New Approval Help This Medical Stock Approach A Breakout?
    Investor's Business Daily22 days ago

    Will A New Approval Help This Medical Stock Approach A Breakout?

    Edwards Lifesciences gained approval for a new transcatheter heart-valve replacement, or TAVR, system Friday — helping its stock to stay within a consolidation.

  • Do Analysts See Any Upside for Abiomed Stock?
    Market Realist23 days ago

    Do Analysts See Any Upside for Abiomed Stock?

    In this year’s second quarter, Abiomed’s (ABMD) net investment income rose YoY (year-over-year) to $1.67 million from $781,000. Abiomed received an income tax benefit of $1.71 million during the second quarter. In comparison, it received an income tax benefit of $7.98 million in the previous year’s period.

  • Examining Abiomed’s Gross Margin Trend
    Market Realist23 days ago

    Examining Abiomed’s Gross Margin Trend

    In the second quarter of 2018, Abiomed’s (ABMD) cost of revenue rose YoY (year-over-year) to $29.85 million from $21.63 million due to higher production volumes and higher costs in support of higher demand for its Impella devices. Its gross margin contracted YoY to 83.58% from 83.72%. Expected trends

  • Exploring Abiomed’s Latest Performance Trends
    Market Realist23 days ago

    Exploring Abiomed’s Latest Performance Trends

    Abiomed (ABMD) provides mechanical circulatory support devices and care for heart failure patients. Its products enable the heart to rest, heal, and recover by improving blood flow and assisting the heart’s pumping function. They are used in the cardiac catheterization lab, by interventional cardiologists, and in heart surgery.

  • Robots, DNA And Implantable Devices — Why 2019 Isn't Your Dad's Medtech
    Investor's Business Daily23 days ago

    Robots, DNA And Implantable Devices — Why 2019 Isn't Your Dad's Medtech

    Innovation will continue in medical technology with a deeper influence from robotics, DNA sequencing and implantable devices, analysts say. Medtech stocks are expected to be strong in 2019.

  • When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
    Simply Wall St.29 days ago

    When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?

    Let's talk about the popular Edwards Lifesciences Corporation (NYSE:EW). The company's shares received a lot of attention from a substantial price movement on the NYSE over the last few months, Read More...

  • Will Walgreens (WBA) Q1 Earnings Gain From Overall Strength?
    Zackslast month

    Will Walgreens (WBA) Q1 Earnings Gain From Overall Strength?

    Several planned developments, early benefits from new pharmacy contracts as well as increased volumes are consistently driving growth within Walgreens Boots' (WBA) Retail Pharmacy USA division.

  • See what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
    Markitlast month

    See what the IHS Markit Score report has to say about Edwards Lifesciences Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.